1Schwartz DA, Pemberton JH, Sandborn WJ. Diagnosis and treatment of perianal fistulas in Crohn disease. Ann Intern Med, 200l, 135 (10): 906-918.
2Lichtenstein GR, Hanauer SB, Sandborn WJ; Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol, 2009, 104 (2): 465-483.
3Present DH, Rutgeerts P, Targan S, et al. Intfiximab forthe treatment of fistulas in patients with Crohn' s disease. N Engl J Med, 1999, 340 (18): 1398-1405.
4Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med, 2004, 350 (9): 876-885.
5Clare DF, Alexander FC, Mike S, et al. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol, 2009, 21 (1): 71-75.
6Bhat S, Sharma D, Doherty P, et al. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease? Inflamm Bowel Dis, 2010, 16 (ll): 1922- 1925.
7Tanaka S, Matsuo K, Sasaki T, et al. Clinical advantages of combined seton placement and infliximab maintenance therapy for perianal fistuhzing Crohn's disease: when and how were the seton drains removed? Hepatogastroenterology, 2010, 57 (97): 3-7.
8Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med, 1995, 123 (2): 132-142.
9Colombel JF, Sandbom WJ, Reinisch W, et al; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med, 2010, 362 (15): 1383-1395.
10Schrtǒder O, Blumenstein I, Stein J. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study. Eur J Gastroenterol Hepatol, 2006, 18 (1): 11-16.
